Allarity Therapeutics Statistics
Total Valuation
ALLR has a market cap or net worth of $15.23 million. The enterprise value is -$8.61 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ALLR has 15.08 million shares outstanding.
| Current Share Class | 15.08M |
| Shares Outstanding | 15.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +157.36% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | 0.60% |
| Float | 15.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.82 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.66, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.66 |
| Quick Ratio | 2.38 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.87 |
Financial Efficiency
Return on equity (ROE) is -383.74% and return on invested capital (ROIC) is -125.64%.
| Return on Equity (ROE) | -383.74% |
| Return on Assets (ROA) | -48.96% |
| Return on Invested Capital (ROIC) | -125.64% |
| Return on Capital Employed (ROCE) | -87.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.43M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -377,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.47% in the last 52 weeks. The beta is 0.03, so ALLR's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -84.47% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 55.83 |
| Average Volume (20 Days) | 431,696 |
Short Selling Information
The latest short interest is 651,765, so 4.32% of the outstanding shares have been sold short.
| Short Interest | 651,765 |
| Short Previous Month | 1.05M |
| Short % of Shares Out | 4.32% |
| Short % of Float | 4.32% |
| Short Ratio (days to cover) | 1.25 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.33M |
| Pretax Income | n/a |
| Net Income | -24.01M |
| EBITDA | -16.32M |
| EBIT | -16.33M |
| Earnings Per Share (EPS) | -$5.47 |
Full Income StatementBalance Sheet
The company has $25.20 million in cash and $1.36 million in debt, giving a net cash position of $23.84 million or $1.58 per share.
| Cash & Cash Equivalents | 25.20M |
| Total Debt | 1.36M |
| Net Cash | 23.84M |
| Net Cash Per Share | $1.58 |
| Equity (Book Value) | 18.67M |
| Book Value Per Share | 1.10 |
| Working Capital | 18.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.64 million and capital expenditures -$298,000, giving a free cash flow of -$18.94 million.
| Operating Cash Flow | -18.64M |
| Capital Expenditures | -298,000 |
| Free Cash Flow | -18.94M |
| FCF Per Share | -$1.26 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
